PL2785359T3 - Mezenchymalne komórki zrębowe i związane z nimi zastosowania - Google Patents

Mezenchymalne komórki zrębowe i związane z nimi zastosowania

Info

Publication number
PL2785359T3
PL2785359T3 PL12854438T PL12854438T PL2785359T3 PL 2785359 T3 PL2785359 T3 PL 2785359T3 PL 12854438 T PL12854438 T PL 12854438T PL 12854438 T PL12854438 T PL 12854438T PL 2785359 T3 PL2785359 T3 PL 2785359T3
Authority
PL
Poland
Prior art keywords
mezenchymal
related applications
rigid cells
rigid
cells
Prior art date
Application number
PL12854438T
Other languages
English (en)
Inventor
Robert Lanza
Erin Anne Kimbrel
Jianlin Chu
Nicholas Arthur Kouris
Original Assignee
Astellas Institute For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48536141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2785359(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Institute For Regenerative Medicine filed Critical Astellas Institute For Regenerative Medicine
Publication of PL2785359T3 publication Critical patent/PL2785359T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A61F2/141—Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/08—Devices or methods enabling eye-patients to replace direct visual perception by another kind of perception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/54—Interprogram communication
    • G06F9/542—Event management; Broadcasting; Multicasting; Notifications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1171—Haematopoietic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2218/00—Aspects of pattern recognition specially adapted for signal processing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
PL12854438T 2011-11-30 2012-11-30 Mezenchymalne komórki zrębowe i związane z nimi zastosowania PL2785359T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565358P 2011-11-30 2011-11-30
PCT/US2012/067464 WO2013082543A1 (en) 2011-11-30 2012-11-30 Mesenchymal stromal cells and uses related thereto
EP12854438.4A EP2785359B1 (en) 2011-11-30 2012-11-30 Mesenchymal stromal cells and uses related thereto

Publications (1)

Publication Number Publication Date
PL2785359T3 true PL2785359T3 (pl) 2018-12-31

Family

ID=48536141

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12854438T PL2785359T3 (pl) 2011-11-30 2012-11-30 Mezenchymalne komórki zrębowe i związane z nimi zastosowania

Country Status (19)

Country Link
US (5) US8962321B2 (pl)
EP (2) EP2785359B1 (pl)
JP (5) JP2015500810A (pl)
KR (4) KR102246369B1 (pl)
CN (2) CN108478599B (pl)
AU (4) AU2012345630A1 (pl)
CA (1) CA2857545A1 (pl)
CY (1) CY1122275T1 (pl)
DK (1) DK2785359T3 (pl)
ES (1) ES2690212T3 (pl)
HR (1) HRP20181515T1 (pl)
HU (1) HUE040566T2 (pl)
LT (1) LT2785359T (pl)
PL (1) PL2785359T3 (pl)
PT (1) PT2785359T (pl)
RS (1) RS57886B1 (pl)
SI (1) SI2785359T1 (pl)
TW (4) TWI698527B (pl)
WO (1) WO2013082543A1 (pl)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651433B1 (ko) * 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
RS57886B1 (sr) 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
EP2872619B1 (en) 2012-07-11 2018-02-14 Imstem Biotechnology Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
KR101669124B1 (ko) * 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물
ES2615396T3 (es) 2013-08-22 2017-06-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin Método para producir músculo cardiaco por ingeniería (EHM)
EP3071688B1 (en) * 2013-11-18 2020-07-08 University of Pittsburgh - Of the Commonwealth System of Higher Education Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
AU2015273799B2 (en) * 2014-06-10 2020-07-02 Mesoblast International Sarl Treatment of immune disorders
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
CN104232573B (zh) * 2014-09-11 2017-01-11 安沂华 一种生长培养基及其用途和培养脐带间充质干细胞的方法
US20160095885A1 (en) * 2014-10-01 2016-04-07 WibiWorks Therapeutics, Inc. Induction Medium & Methods for Stem Cell Culture & Therapy
CN104531613B (zh) * 2014-11-17 2017-12-19 中国农业科学院北京畜牧兽医研究所 Wip1敲除在促进小鼠骨髓间充质干细胞迁移中的应用
CA3247653A1 (en) * 2014-12-23 2025-10-31 Mesoblast International Sarl Method for treating heart failure
ES2980659T3 (es) 2015-03-23 2024-10-02 Astellas Inst For Regenerative Medicine Ensayos mejorados de potencia de células de epitelio pigmentario retiniano (EPR) humano y progenitores de fotorreceptores
DK3331994T3 (da) 2015-08-05 2022-11-21 Cell Cure Neurosciences Ltd Fremstilling af retinale pigmentepitelceller
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
EP3356515B1 (en) * 2015-09-29 2024-06-05 Celularity Inc. Cell potency assay
EP3359645A1 (en) * 2015-10-05 2018-08-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method and culture medium for ex vivo culturing of epidermis-derived stem cells
HK1254739A1 (zh) * 2015-11-04 2019-07-26 The Board Of Regents Of The University Of Texas System 从年长细胞群中富集和扩增高潜能人间充质干细胞
CN108289915A (zh) * 2015-11-24 2018-07-17 日本乐敦制药株式会社 包含脂肪组织来源基质细胞的肝病治疗剂及其制造方法
CN105326864A (zh) * 2015-11-30 2016-02-17 奥思达干细胞有限公司 一种治疗系统性红斑狼疮的干细胞制剂及其制备方法
US10383895B2 (en) * 2016-02-18 2019-08-20 Viera Bioscience, Inc. Stimulation of therapeutic angiogenesis by T regulatory cells
CN105671000A (zh) * 2016-03-02 2016-06-15 深圳爱生再生医学科技有限公司 重组间充质干细胞及其制备方法和应用
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
US20190224244A1 (en) * 2016-07-11 2019-07-25 Bonus Therapeutics Ltd. Cell compositions for tissue regeneration
CN106267161A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种干细胞制剂及其制备方法和应用
CN106265899A (zh) * 2016-09-30 2017-01-04 广州赛莱拉干细胞科技股份有限公司 一种组合物及其在制备改善慢性鼻炎的产品中的应用
CN106520686A (zh) * 2016-10-11 2017-03-22 海南博鳌龄迈迪精准医学研究院有限公司 脂肪间充质干细胞的培养方法
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
KR101971322B1 (ko) * 2016-10-17 2019-04-23 사회복지법인 삼성생명공익재단 Ｓｏｃｓ의　발현　또는　활성　억제를　이용한　고효능 줄기세포 선별방법
CA3042360A1 (en) * 2016-11-03 2018-05-11 Exostem Biotec Ltd. Mesenchymal stem cells populations, their products, and use thereof
CN106619721A (zh) * 2016-11-08 2017-05-10 中国人民解放军军事医学科学院野战输血研究所 一种增强细胞活性的新方法
CN106581760A (zh) * 2016-11-08 2017-04-26 华南生物医药研究院 增强细胞活性的特殊处理方法
CN106563161A (zh) * 2016-11-08 2017-04-19 华南生物医药研究院 可用于美容的新型药物组合剂
KR102390909B1 (ko) * 2016-12-19 2022-04-26 주식회사 파이안바이오테크놀로지 미토콘드리아를 포함하는 허혈성 질환 예방 또는 치료용 조성물
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
GB201703058D0 (en) * 2017-02-24 2017-04-12 Ucl Business Plc Biomarkers
EP3608400B1 (en) 2017-04-03 2025-03-26 Kaneka Corporation Cell population including mesenchymal stem cells, production method therefor, and pharmaceutical composition
WO2018207918A1 (ja) * 2017-05-12 2018-11-15 国立大学法人 東京医科歯科大学 移植効率を向上させる間葉系幹細胞の純化方法
AU2018289935A1 (en) * 2017-06-19 2020-01-23 Life Science Institute, Inc. Treatment agent for epidermolysis bullosa
CN107490701B (zh) * 2017-08-17 2021-09-14 上海集技生物技术有限公司 一种基于局部照射的全身性骨损伤模型的建立及病理机制分析的方法
CN107714726A (zh) 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
CN109069543B (zh) * 2017-10-16 2020-02-18 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
EP3707515A1 (en) * 2017-11-06 2020-09-16 Kings College London Therapeutic substances, their preparation and diagnostic procedure
KR102095628B1 (ko) * 2018-01-05 2020-04-01 재단법인 아산사회복지재단 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물
PL3752598T3 (pl) * 2018-02-16 2023-03-13 Nextcell Pharma Ab Kompozycja allogeniczna
WO2019171386A1 (en) * 2018-03-07 2019-09-12 The Medical Research Infrastructure And Health Services Fund Of The Tel-Aviv Medical Center Compositions and methods for treating age-related macular degeneration
US11413314B2 (en) * 2018-06-15 2022-08-16 NextPhase Therapeutics, Inc. Pharmaceutical composition for dermatology and uses thereof
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
CN109082409A (zh) * 2018-09-14 2018-12-25 四川新生命干细胞科技股份有限公司 一种组织修复能力强的脂肪干细胞分离培养及筛选方法
CN109182262A (zh) * 2018-09-25 2019-01-11 深圳市五零生命科技有限公司 一种间充质干细胞无血清培养基
EP3886759A1 (en) * 2018-11-26 2021-10-06 Massachusetts Institute of Technology Compositions and methods for immune tolerance
CN109342739A (zh) * 2018-11-27 2019-02-15 上海科医联创生物科技有限公司 一种鉴定间充质干细胞纯度的方法
CN109609584A (zh) * 2018-12-10 2019-04-12 天津长和生物技术有限公司 间充质干细胞免疫调节能力的检测方法
US20220202868A1 (en) * 2019-02-27 2022-06-30 Tigenix S.A.U. Improved stem cell populations for allogeneic therapy
WO2020182935A1 (en) * 2019-03-12 2020-09-17 Global Stem Cell Technology Immunomodulating mesenchymal stem cells
JP7541699B2 (ja) 2019-03-14 2024-08-29 北海道公立大学法人 札幌医科大学 筋萎縮性側索硬化症の治療用医薬組成物
EP4004191A4 (en) 2019-07-26 2022-10-12 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same
CN110305839A (zh) * 2019-08-02 2019-10-08 陕西佰傲干细胞再生医学有限公司 间充质干细胞无血清培养基
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
CA3151637A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Methods of treating vascular diseases
CN110564674B (zh) * 2019-09-29 2021-05-11 广东工业大学 一种干细胞铺底工作液及其应用
WO2021072595A1 (zh) * 2019-10-14 2021-04-22 玛旺干细胞医学生物科技股份有限公司 间充质干细胞在治疗听力障碍上的医药用途
RU2740152C1 (ru) * 2020-01-09 2021-01-13 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр "Красноярский научный центр Сибирского отделения Российской академии наук" (ФИЦ КНЦ СО РАН) Способ активации пролиферативного ответа фибробластоподобных клеток стромально-васкулярной фракции жировой ткани
WO2021169017A1 (zh) * 2020-02-25 2021-09-02 上海大学 间充质干细胞在治疗重症covid19肺炎中的用途
CN115297877A (zh) * 2020-04-13 2022-11-04 国立大学法人东海国立大学机构 肾脏中cd25阳性调节性t细胞增加剂
WO2021222389A1 (en) * 2020-04-28 2021-11-04 Factor Bioscience Inc. Mesenchymal stem cell therapies
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111518761B (zh) * 2020-05-25 2022-04-29 青岛瑞思德生物科技有限公司 一种间充质干细胞体外筛选、激活、扩增、冻存及其细胞库建立的方法
WO2022004938A1 (ko) * 2020-06-30 2022-01-06 주식회사 미래셀바이오 유사 중간엽 줄기세포의 제조방법
EP3945133A1 (en) * 2020-07-29 2022-02-02 Georg-August-Universität Göttingen Mass production of human pluripotent stem cell derived cardiac stromal cell
CN112826833A (zh) * 2020-07-30 2021-05-25 中国人民解放军总医院第五医学中心 间充质干细胞在制备新冠肺炎引起的肺损伤修复药物中的应用
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
WO2022086276A1 (ko) * 2020-10-22 2022-04-28 가톨릭대학교 산학협력단 특정 유전자의 발현이 증가 또는 감소된 줄기세포를 유효성분으로 포함하는 류마티스 관절염 예방 또는 치료용 약학적 조성물
JP7731997B2 (ja) * 2021-05-07 2025-09-01 スンクワン メディカル ファウンデーション 骨分化能機能強化の間葉系幹細胞、及びその用途
TW202320819A (zh) * 2021-07-08 2023-06-01 比利時商比利時百靈佳殷格翰動物醫藥公司 用於治療慢性齦口炎之間葉幹細胞
CN113717972B (zh) * 2021-08-16 2022-07-01 南通市肿瘤医院 MYADM靶向的siRNA及其应用
US20240424027A1 (en) * 2021-10-12 2024-12-26 Mechanogenic K.K. Anti-Aging Composition Using Mesenchymal Stem Cells and Methods Thereof
CA3243344A1 (en) * 2022-02-07 2023-08-10 Smartcella Solutions Ab METHODS AND COMPOSITIONS FOR GENERATING HUMAN INDUCED MESENCHYMATOUS STEM CELLS
CN114984051A (zh) * 2022-06-27 2022-09-02 广州惠善医疗技术有限公司 间充质干细胞在制备治疗炎症及免疫相关疾病的药物中的应用
WO2024007038A2 (en) * 2022-07-01 2024-01-04 Northwestern University Compositions and methods for the treatment of intestinal inflammation
US20250257321A1 (en) 2022-07-18 2025-08-14 Astellas Institute For Regenerative Medicine Methods of treating brain injury
CN115305234B (zh) 2022-09-28 2023-01-17 呈诺再生医学科技(北京)有限公司 一种制备间充质干细胞的方法、间充质干细胞和应用
JP7725119B2 (ja) * 2023-01-27 2025-08-19 株式会社Rainbow 自動培養装置における細胞増殖制御方法
TW202434721A (zh) * 2023-02-14 2024-09-01 國立大學法人山口大學 細胞群、三維細胞培養體、醫藥組成物、胞泌體及製作此細胞群的方法
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法
CN117210528B (zh) * 2023-09-12 2024-08-20 长沙干细胞与再生医学工业技术研究院有限公司 一种综合评估间充质干细胞免疫调控能力的方法
WO2025084581A1 (ko) * 2023-10-18 2025-04-24 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포를 포함하는 복막 섬유증의 개선, 예방 또는 치료용 조성물
CN121137073B (zh) * 2025-11-17 2026-05-01 上海兴瑞一达生物科技有限公司 一种抗IL-11抗体修饰的Treg细胞的制备方法及其应用

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6416581A (en) * 1987-07-09 1989-01-20 Rikagaku Kenkyusho Frozen animal cell and production thereof
US5128259A (en) 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
AU1595195A (en) 1993-12-23 1995-07-10 Abs Global, Inc. Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
JP2002515756A (ja) 1997-01-31 2002-05-28 ヘモソル インク． 選択されたリンパ球の生産方法
WO1998053048A1 (en) 1997-05-21 1998-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US6429012B1 (en) 1997-10-06 2002-08-06 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
EP1108011A2 (en) 1998-06-08 2001-06-20 Osiris Therapeutics, Inc. In vitro maintenance of hematopoietic stem cells
US6361998B1 (en) 1998-06-25 2002-03-26 Hemosol Inc. Efficient culture of stem cells for the production of hemoglobin
EP1270719A3 (en) 1998-08-24 2003-06-25 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
US20110171185A1 (en) 1999-06-30 2011-07-14 Klimanskaya Irina V Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof
MXPA02003733A (es) 1999-10-15 2003-10-14 Advanced Cell Tech Inc Metodos para producir celulas progenitoras diferenciadas y celulas troncales embrionicas de lineas de descendencia defectivas.
CN1423523A (zh) 1999-11-17 2003-06-11 罗切斯特大学 来自人体内的免疫系统
US20020035735A1 (en) 2000-01-07 2002-03-21 Gerald Schatten Clonal propagation of primate offspring by embryo splitting
WO2001053465A1 (en) 2000-01-21 2001-07-26 The Johns Hopkins University School Of Medicine Human embryoid body-derived cells
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
JP2004504834A (ja) 2000-08-01 2004-02-19 イスム　リサーチ　ディベロップメント　カンパニー 胚性細胞の定方向分化
AU9109201A (en) 2000-09-18 2002-03-26 Organogenesis Inc Methods for treating a patient using a bioengineered flat sheet graft prostheses
AU2002335610C1 (en) 2001-01-29 2008-09-25 Hemogenix, Inc. High-throughput stem cell assay of hematopoietic stem and progenitor cell proliferation
WO2002078449A2 (en) 2001-04-02 2002-10-10 Advanced Cell Technology, Inc. Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
KR20020083634A (ko) 2001-04-27 2002-11-04 크레아젠 주식회사 수지상 세포를 포함하는 자가면역 질환의 치료용 약제학적조성물 및 이를 이용한 치료방법
JP2004531262A (ja) 2001-05-15 2004-10-14 ラッパポート ファミリー インスチチュート フォア リサーチ イン ザ メディカル サイエンシズ ヒト胚性幹細胞由来インスリン産生細胞
US20050042751A1 (en) 2001-10-31 2005-02-24 Michel Goldman Generation and use of new types of dendritic cells
JP4085062B2 (ja) 2001-11-02 2008-04-30 ウイスコンシン アラムニ リサーチ ファンデーション 霊長類の胚性幹細胞から由来した内皮細胞
WO2003042405A2 (en) 2001-11-15 2003-05-22 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
MXPA04005010A (es) 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
EP2292734A1 (en) 2001-12-07 2011-03-09 Geron Corporation Hematopoietic cells from human embryonic stem cells
WO2003080116A1 (en) 2002-03-21 2003-10-02 University Of Florida Modulating angiogenesis
WO2004007698A1 (en) 2002-07-12 2004-01-22 National University Of Singapore Hemangioblast progenitor cells
US20040052771A1 (en) 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
AR047712A1 (es) 2002-09-07 2006-02-15 Royal Veterinary College Metodo de tratamiento de una lesion de tejido esqueletico blando natural administrando una composicion de celulas madre mesenquimatosas
AU2003273332A1 (en) 2002-09-26 2004-04-19 Children's Medical Center Corporation Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
AU2002348947A1 (en) 2002-09-26 2004-04-19 Institut National De La Sante Et De La Recherche Medicale Compositions and methods for amplification of human stem cells
WO2004044146A2 (en) 2002-11-06 2004-05-27 Piniella Carlos J Pluripotent cells from monocytes, and methods of making and using pluripotent cells
US20040156878A1 (en) 2003-02-11 2004-08-12 Alireza Rezania Implantable medical device seeded with mammalian cells and methods of treatment
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
EP1624751A2 (en) 2003-05-08 2006-02-15 Cellartis AB Cryopreservation of human blastocyst-derived stem cells by use of a closed straw vitrification method
US20040229350A1 (en) 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
WO2005040391A1 (en) 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells
US20070141703A1 (en) 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture
JP2007520462A (ja) 2003-12-19 2007-07-26 バイアセル インコーポレーティッド ヒト臍帯血由来多能性細胞の疾患の処置のための使用方法
CN1286970C (zh) 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
WO2005068610A1 (en) 2004-01-02 2005-07-28 Advanced Cell Technology, Inc. Novel culture systems for ex vivo development
KR100535326B1 (ko) 2004-01-20 2005-12-09 한국생명공학연구원 줄기 세포로부터 자연살해 세포로의 분화 조절용 유전자를유효성분으로 포함하는 분화 조절제
AU2005207042B2 (en) 2004-01-23 2010-09-09 President And Fellows Of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
CA2554094A1 (en) 2004-02-09 2005-08-25 Indiana University Research And Technology Corporation Isolation, expansion and use of clonogenic endothelial progenitor cells
EP2298863B1 (en) 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP1735429A4 (en) 2004-03-31 2008-06-11 Newlink Genetics Corp METHOD AND COMPOSITIONS FOR OBTAINING EMBRYONAL STEM CELLS OF ABSTINENT HEMATOPOETIC STEM CELLS AND USES THEREOF
EP1743023A1 (en) 2004-05-07 2007-01-17 Wisconsin Alumni Research Foundation Method of forming mesenchymal stem cells from embryonic stem cells
JP4980211B2 (ja) * 2004-05-12 2012-07-18 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 細胞単離方法
JP5139799B2 (ja) 2004-06-04 2013-02-06 ユニベルシテ ピエール エ マリー キュリー（パリ シズエム） 赤血球細胞の生産方法
CA2571844A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing minus-strand rna virus
CA2580975A1 (en) 2004-09-24 2006-03-30 Angioblast Systems, Inc. Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
AU2005302258B2 (en) 2004-11-01 2010-10-21 Wisconsin Alumni Research Foundation Platelets from stem cells
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US20080166751A1 (en) 2005-02-23 2008-07-10 Takayuki Asahara Method of Analyzing Dynamics in the Differentiation of Vascular Endothelial Progenitor Cells
US8492148B2 (en) 2005-02-23 2013-07-23 Foundation For Biomedical Research & Innovation Method for amplification of endothelial progenitor cell in vitro
JP2006230316A (ja) * 2005-02-25 2006-09-07 Japan Health Science Foundation 瘢痕のない創傷治癒能を有する細胞およびその調製方法
WO2006097743A2 (en) 2005-03-17 2006-09-21 Ucl Biomedica Plc Method for actvating natural killer cells by tumor cell preparation in vitro
KR20150032915A (ko) 2005-04-08 2015-03-30 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
EP1891438A4 (en) 2005-05-27 2008-12-10 Advanced Cell Tech Inc METHOD OF IDENTIFYING LIGANDS FOR STEM CELLS AND CELLS DERIVED FROM THESE
GB2440494B (en) 2005-06-01 2010-07-28 Wisconsin Alumni Res Found Method of forming dendritic from embryonic stem cells
WO2007005595A1 (en) 2005-07-05 2007-01-11 The New England Medical Center Hospitals, Inc. Pregnancy-associated progenitor cells
CA2659945C (en) 2005-08-03 2014-12-16 Advanced Cell Technology, Inc. Improved methods of reprogramming animal somatic cells
US8198085B2 (en) 2005-08-03 2012-06-12 Core Dynamics Limited Somatic cells for use in cell therapy
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
JP2007089432A (ja) 2005-09-27 2007-04-12 Reprocell Inc 幹細胞由来血小板産生増加法
DK1941027T3 (da) 2005-09-28 2014-10-13 Ipd Therapeutics B V Fremgangsmåder og midler til stamcelleforøgelse og efterfølgende generering og ekspansion af progenitorceller samt produktion af effektorceller som kliniske terapeutika
US20090271335A1 (en) 2005-10-20 2009-10-29 Advanced Cell Technology, Inc. Totipotent, Nearly Totipotent or Pluripotent Mammalian Cells Homozygous or Hemizygous for One or More Histocompatibility Antigent Genes
CN101365784A (zh) 2005-10-24 2009-02-11 科学技术研究公司 确定中胚层、内胚层和中内胚层细胞命运的方法
WO2007062198A1 (en) 2005-11-21 2007-05-31 Advanced Cell Technology, Inc. Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
EP3287520A1 (en) 2006-01-13 2018-02-28 Mesoblast International Sàrl Mesenchymal stem cells expressing tnf-alpha receptors
GB2449042B (en) 2006-02-09 2010-07-07 Wisconsin Alumni Res Found Erythroid cells producing adult-type b-hemoglobin generated from human embryonic stem cells
JP2009531021A (ja) * 2006-02-16 2009-09-03 フォンダッチォーネ・セントロ・サン・ラファエル・デル・モンテ・タボール 骨格筋周囲血管芽細胞および心筋中胚葉性血管芽細胞、それらの単離および使用方法
EP1996698A1 (en) * 2006-03-01 2008-12-03 Cartela R&D AB Expansion and differentiation of mesenchymal stem cells
CN101045915A (zh) 2006-03-29 2007-10-03 旭日干 一种卵母细胞生发泡移植技术
CN101045914A (zh) 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用
KR102651433B1 (ko) 2006-04-14 2024-03-25 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
AU2013201444B2 (en) 2006-04-14 2015-01-22 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
NZ572842A (en) 2006-04-14 2012-01-12 Advanced Cell Tech Inc Hemangio-colony forming cells
KR100791487B1 (ko) * 2006-05-29 2008-01-03 연세대학교 산학협력단 제대혈로부터 간엽줄기세포의 분리 및 배양 방법
US20070298496A1 (en) 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
JP2010500047A (ja) 2006-08-15 2010-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間葉系幹細胞馴化培地
ES2583371T3 (es) 2006-10-11 2016-09-20 The General Hospital Corporation Composiciones, métodos, y dispositivos para tratar enfermedades hepáticas
WO2008067142A2 (en) 2006-11-08 2008-06-05 Wisconsin Alumni Research Foundation In vitro differentiation of hematopoietic cells from primate embryonic stem cells
EP2088190A4 (en) 2006-11-09 2011-01-05 Japan Government METHOD FOR THE CULTURE AND PASSING OF AN EMBRYONAL PRIMATIVE STEM CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF THE EMBRYONAL STEM CELL
DE102006054041B3 (de) 2006-11-16 2008-05-08 Pierburg Gmbh Regelvorrichtung für eine Verbrennungskraftmaschine
WO2008103462A2 (en) 2007-02-23 2008-08-28 Advanced Cell Technology, Inc. Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells
AU2008260651B2 (en) 2007-05-24 2014-06-12 Apceth Gmbh & Co. Kg CD34 stem cell-related methods and compositions
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2008151386A1 (en) 2007-06-15 2008-12-18 Australian Stem Cell Centre Ltd Megakaryocyte differentiation
US9095562B2 (en) * 2007-07-05 2015-08-04 Regenerative Sciences, Inc. Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
CN101827603B (zh) 2007-08-06 2013-03-06 成血管细胞系统公司 用于体内生成、修复和/或维护结缔组织的方法
KR101039235B1 (ko) * 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
US20110236971A2 (en) 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
CA2700617C (en) 2007-09-28 2018-11-06 Celgene Cellular Therapeutics Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CN104946591A (zh) 2007-10-12 2015-09-30 奥卡塔治疗公司 制备rpe 细胞和rpe 细胞的组合物的改良方法
US20100304480A1 (en) 2007-10-19 2010-12-02 Goodell Margaret A Hematopoietic Fingerprints: Methods of Use
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
US8685728B2 (en) 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
US10046011B2 (en) 2008-01-31 2018-08-14 Rutgers, The State University Of New Jersey Compositions for inducing or suppressing an immune response
JP5728234B2 (ja) 2008-02-15 2015-06-03 ボーン・セラピューティクス 骨関節疾患の治療又は予防において使用するための医薬組成物
WO2009104825A1 (en) * 2008-02-18 2009-08-27 Kaist Method for inducing the defferentiation of embryonic stem cells into hemangioblast
EP2712921B1 (en) 2008-05-06 2018-07-11 Astellas Institute for Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
BE1018748A3 (fr) 2008-05-07 2011-08-02 Bone Therapeutics Sa Nouvelles cellules souches mesenchymateuses et cellules osteogeniques .
AU2009279736A1 (en) * 2008-08-04 2010-02-11 Allocure, Inc. Mesenchymal stromal cell populations and methods of isolating and using same
WO2010025506A1 (en) 2008-09-03 2010-03-11 Angioblast Systems, Inc. Expansion of haemopoietic precursors
FR2938947B1 (fr) 2008-11-25 2012-08-17 A Volute Procede de traitement du signal, notamment audionumerique.
EP2221362A1 (en) 2009-02-19 2010-08-25 Naturin GmbH & Co Method for the cryopreservation of cells, artificial cell constructs or three-dimensional complex tissues assemblies
CN102388130B (zh) 2009-02-27 2014-08-27 细胞动力国际有限公司 多能细胞的分化
US20120114618A1 (en) 2009-03-26 2012-05-10 The Regents Of The University Of California Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification
JP2010252778A (ja) * 2009-04-02 2010-11-11 Shizui Bank Kk 歯髄由来間葉系幹細胞の分離方法及び分離した幹細胞並びにそれらを用いた肝細胞系譜への分化
WO2011004264A1 (en) 2009-07-09 2011-01-13 Cellerix Sa Methods and compositions for use in cellular therapies
CA2776882A1 (en) * 2009-10-06 2011-04-14 The Cohen Mcniece Foundation Preparation and use of stromal cells for treatment of cardiac diseases
WO2011047345A2 (en) 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
WO2011053860A2 (en) 2009-10-30 2011-05-05 Allocure, Inc. Mesenchymal stromal cell populations and methods of using same
EP2501802A4 (en) 2009-11-17 2013-08-21 Advanced Cell Tech Inc METHOD FOR PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS FROM HUMAN RPE CELLS
US8900860B2 (en) * 2009-11-30 2014-12-02 National Yang-Ming University Method for expanding mesenchymal stem cells in low-density and hypoxic culture
KR20180086301A (ko) 2009-12-04 2018-07-30 스템 셀 앤드 리제너러티브 메디신 인터내셔날, 인크. 기질 없는 조건 하에서 인간 배아줄기세포로부터 기능적 거핵구 및 혈소판의 대규모 생성
BR112012014104A2 (pt) 2009-12-04 2016-07-05 Stem Cell & Regenerative Medicine International Inc método de geração de células destrutoras naturais e células dendríticas de hemangioblastos embrionários humanos derivados de células-tronco
EP2531593A4 (en) * 2010-02-02 2013-08-28 Univ Rochester PROCESS FOR THE ISOLATION AND CULTIVATION OF MESENCHYMAL STEM CELLS
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
JP5804385B2 (ja) 2010-03-10 2015-11-04 株式会社ツーセル 間葉系幹細胞を含む細胞製剤及びその製造方法
WO2011124741A1 (es) 2010-04-08 2011-10-13 Fundación Progreso Y Salud Uso de un medio de cultivo condicionado por células madre mesenquimales para la diferenciación de células madre pluripotentes humanas
WO2011139132A2 (ko) 2010-05-07 2011-11-10 한국생명공학연구원 줄기세포로부터 생성된 배아체를 대량 증식 및 유지하는 방법
JP5805195B2 (ja) 2010-08-23 2015-11-04 カンステム バイオテック カンパニー リミテッド Ｎｏｄ２アゴニストで処理した幹細胞またはその培養物を含む免疫疾患および炎症性疾患の予防および治療用の薬学的組成物
EP4663241A3 (en) 2010-10-08 2026-03-25 Mesoblast International Sàrl Enhanced msc preparations
KR20120095022A (ko) 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 간엽줄기세포 및 면역조절 ｔ 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물
RS57886B1 (sr) 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
KR101477016B1 (ko) 2012-01-19 2014-12-29 (주)차바이오텍 인간 배아줄기세포 유래 혈관주위 전구세포의 제조방법 및 이를 포함하는 세포치료 조성물
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
KR102353601B1 (ko) 2012-12-14 2022-01-19 럿거스, 더 스테이트 유니버시티 오브 뉴저지 줄기세포의 면역조절성 효과의 조절 방법
US20160008401A1 (en) 2013-03-01 2016-01-14 Apceth Gmbh & Co. Kg Protection of the vascular endothelium from immunologically mediated cytotoxic reactions with human cd34-negative progenitor cells
KR101669124B1 (ko) 2013-07-11 2016-10-25 서울대학교병원 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물
CN106255884B (zh) 2013-10-04 2019-01-11 赛尔爱迪尔私人有限公司 用于细胞治疗的生物标志物
EP3107995B1 (en) 2014-02-18 2019-10-30 Massachusetts Institute Of Technology Biophysically sorted osteoprogenitors from culture expanded bone marrow derived mesenchymal stromal cells (mscs)
AU2015273799B2 (en) 2014-06-10 2020-07-02 Mesoblast International Sarl Treatment of immune disorders
JP6459257B2 (ja) 2014-07-08 2019-01-30 富士ゼロックス株式会社 画像形成装置
US20170204151A1 (en) 2014-07-28 2017-07-20 Darwin J. Prockop Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders
JP6998768B2 (ja) 2015-08-28 2022-02-10 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞及びその調製方法、ｒｏｒ１陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる疾患の予防又は治療方法
EP3369810A4 (en) 2015-10-27 2019-05-01 Kaneka Corporation METHOD FOR PRODUCING CELL POPULATION WITH MESENCHYMAL STEM CELLS, MESENCHYMAL STEM CELLS, CELL POPULATION AND PHARMACEUTICAL COMPOSITION
EP3385368B1 (en) 2015-12-03 2023-03-01 Takara Bio Inc. Method for producing mesenchymal stem cells
JP7048977B2 (ja) 2016-03-16 2022-04-06 サイナータ セラピューティクス リミテッド コロニー形成培地及びその使用
EP3450548A4 (en) 2016-04-27 2019-11-20 Rohto Pharmaceutical Co., Ltd. MESCHYMAL STEM CELL FOR EXPRESSING AT LEAST ONE CELL SURFACE MARKER SELECTED FROM THE GROUP OF CD201, CD46, CD56, CD147 AND CD165, AND METHOD FOR THE MANUFACTURE THEREOF AND PHARMACEUTICAL COMPOSITION WITH THE MESENCHYMAL STEM CELL AND METHOD FOR THE PRODUCTION THEREOF
KR101816246B1 (ko) 2016-09-07 2018-01-08 에스씨엠생명과학 주식회사 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물
CA3042031A1 (en) 2016-10-27 2018-05-03 The Trustees Of Columbia University In The City Of New York Immunosuppressive mesenchymal cells and methods for forming same
PT3551748T (pt) 2016-12-12 2022-09-29 Health And Biotech France H&B France Células estaminais do mesênquima derivadas de tecido perinatal: método de preparação e suas utilizações
EP3608400B1 (en) 2017-04-03 2025-03-26 Kaneka Corporation Cell population including mesenchymal stem cells, production method therefor, and pharmaceutical composition
WO2018186419A1 (ja) 2017-04-03 2018-10-11 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN110753751A (zh) 2017-05-04 2020-02-04 迈索布拉斯特国际有限公司 具有增强的免疫抑制的间充质谱系前体或干细胞

Also Published As

Publication number Publication date
KR20140127209A (ko) 2014-11-03
HRP20181515T1 (hr) 2018-11-16
TW202037373A (zh) 2020-10-16
US20130183272A1 (en) 2013-07-18
US20250090590A1 (en) 2025-03-20
AU2022202639A1 (en) 2022-05-12
US20160038543A1 (en) 2016-02-11
JP6526130B2 (ja) 2019-06-05
US20210182552A1 (en) 2021-06-17
US8962321B2 (en) 2015-02-24
US12097223B2 (en) 2024-09-24
AU2012345630A1 (en) 2014-07-17
WO2013082543A1 (en) 2013-06-06
JP2018027954A (ja) 2018-02-22
TWI698242B (zh) 2020-07-11
TW202344258A (zh) 2023-11-16
AU2022202639B2 (en) 2025-06-12
AU2019264631A1 (en) 2019-12-05
EP2785359A4 (en) 2015-11-11
CN104136034A (zh) 2014-11-05
JP2024067032A (ja) 2024-05-16
CN108478599A (zh) 2018-09-04
SI2785359T1 (sl) 2018-11-30
PT2785359T (pt) 2018-11-06
CA2857545A1 (en) 2013-06-06
EP2785359B1 (en) 2018-08-29
TWI698527B (zh) 2020-07-11
KR20200051827A (ko) 2020-05-13
JP2019142958A (ja) 2019-08-29
KR20230059838A (ko) 2023-05-03
JP6983195B2 (ja) 2021-12-17
LT2785359T (lt) 2018-11-12
TWI812867B (zh) 2023-08-21
AU2019264631B2 (en) 2022-01-20
EP3449929B1 (en) 2025-11-19
JP2022027796A (ja) 2022-02-14
EP3449929A1 (en) 2019-03-06
ES2690212T3 (es) 2018-11-19
TW202537630A (zh) 2025-10-01
DK2785359T3 (en) 2018-10-29
KR102108245B1 (ko) 2020-05-08
US20170252374A1 (en) 2017-09-07
CY1122275T1 (el) 2020-07-31
RS57886B1 (sr) 2019-01-31
CN104136034B (zh) 2018-04-24
JP7777430B2 (ja) 2025-11-28
HUE040566T2 (hu) 2019-03-28
KR102811933B1 (ko) 2025-05-23
KR102525175B1 (ko) 2023-04-21
AU2017239526B2 (en) 2019-08-15
TW201815399A (zh) 2018-05-01
HK1202798A1 (en) 2015-10-09
JP2015500810A (ja) 2015-01-08
AU2017239526A1 (en) 2017-10-26
KR102246369B1 (ko) 2021-04-29
TW201331365A (zh) 2013-08-01
EP2785359A1 (en) 2014-10-08
KR20210044904A (ko) 2021-04-23
CN108478599B (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
DK2837680T3 (da) Mammaliacellekultur
DK2775557T3 (da) Brændselscelle
EP2664017A4 (en) STACK OF FLOW CELLS
HRP20182098T1 (hr) Anti-angptl3 antitijela i njihove primjene
DK3442233T3 (da) Nedarvning i samplearraymultitræsunderinddeling
DK2552261T3 (da) Propfilter med proprum med aromakugle
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
HRP20181152T1 (hr) Progenitorne stanice mezodermalnog porijekla
EP2557610A4 (en) Cell module
EP3719852C0 (en) SOLAR CELL
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
DK2683643T3 (da) Prostatacancercellelinjer, gensignaturer og anvendelser deraf
EP2535261A4 (en) SCHAUFELRADJACHT
EP3701800C0 (en) Use
BR112013007852A2 (pt) pilha reforçada aperfeiçoada
DK2912165T3 (da) Nyrecellepopulationer og anvendelser deraf
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
IL235125A0 (en) Microbial fuel cell
EP2610945A4 (en) STACK CELL
EP2654170A4 (en) CHARGER
EP2831949A4 (en) SODIUM OXYGEN CELLS
DK2753346T3 (da) Ceramidase og celledifferentiering
EP2613418A4 (en) CHARGER
EP2544283A4 (en) Fuel cell